Gain Therapeutics climbs on narrower-than-expected quarterly loss - GANX News | RalliesGain Therapeutics climbs on narrower-than-expected quarterly loss
G
GANX• Quarterly loss and R&D spending come in below expectations
- Shares of drug developer Gain Therapeutics (GANX.O) rise 5.4% to $1.86.
- GANX reports Q2 loss of 11 cents/shr vs analysts' average loss estimate of 14 cents/shr, according to LSEG data.
- Co's R&D expense decreased by $0.6 million to $2.1 million for the three months ended June 30, compared to $2.8 million a year ago.
- Analysts on average expected R&D expense of $3.18 million.
- Co's cash and its equivalents were $13.1 million as of June 30, compared to $20.8 million as of December 31, 2025.
- Including session's move, stock down 42.5% YTD.
•
